Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) has recently emphasized the significant advantages of its IzoView Breast CT Imaging System compared to current breast imaging technologies. The system provides true 3D, ultra-high-resolution imaging without the need for breast compression, positioning itself as a crucial innovation between digital breast tomosynthesis and MRI. Licensed globally from UC Davis, IzoView boasts 100 times greater spatial resolution than MRI, at a reduced cost and with quicker scan times, aiming to enhance screening, diagnosis, and treatment planning, especially for women with dense breast tissue.
The development of the IzoView Breast CT Imaging System represents a potential leap forward in the fight against breast cancer, offering a less invasive and more accurate diagnostic tool. This technology could significantly impact the medical imaging industry by setting new standards for breast cancer detection and treatment planning. For patients, particularly those with dense breast tissue who often face challenges with current imaging methods, the IzoView system promises a more comfortable and efficient diagnostic experience.
For more detailed information on the IzoView Breast CT Imaging System, visit https://ibn.fm/NbLB2.
